According to Repligen 's latest financial reports the company's total debt is $0.71 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2023-12-31 | $0.71 B | 68.29% |
2022-12-31 | $0.42 B | 15.55% |
2021-12-31 | $0.36 B | 32.91% |
2020-12-31 | $0.27 B | 4.59% |
2019-12-31 | $0.26 B | 154.44% |
2018-12-31 | $0.10 B | 4.27% |
2017-12-31 | $99.25 M | 4.18% |
2016-12-31 | $95.27 M | |
2005-03-31 | $0.11 M | 40% |
2004-03-31 | $0.08 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $70.84 B | 9,852.88% | ๐บ๐ธ USA |
Thermo Fisher Scientific TMO | $34.91 B | 4,805.42% | ๐บ๐ธ USA |
General Electric GE | $20.52 B | 2,783.52% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $41.46 B | 5,725.20% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $38.1 M | -94.65% | ๐บ๐ธ USA |
Novavax NVAX | $0.22 B | -67.82% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $0.42 B | -39.81% | ๐บ๐ธ USA |
Bio-Techne TECH | $0.55 B | -21.93% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $1.09 B | 53.94% | ๐บ๐ธ USA |
Charles River Laboratories
CRL | $3.06 B | 330.79% | ๐บ๐ธ USA |